Shares of Evommune, Inc. (NYSE:EVMN – Get Free Report) have been given a consensus rating of “Moderate Buy” by the fourteen research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $45.6250.
EVMN has been the topic of a number of recent research reports. Morgan Stanley lowered their price objective on Evommune from $55.00 to $26.00 and set an “overweight” rating on the stock in a research note on Tuesday, June 30th. Wall Street Zen downgraded Evommune from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Weiss Ratings lowered Evommune from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, June 29th. Raymond James Financial cut Evommune from a “strong-buy” rating to a “moderate buy” rating in a research report on Monday, June 29th. Finally, William Blair downgraded Evommune from an “outperform” rating to a “market perform” rating in a research note on Monday, June 29th.
View Our Latest Report on Evommune
Evommune Stock Down 8.1%
Evommune (NYSE:EVMN – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.19. Equities analysts expect that Evommune will post -2.83 EPS for the current year.
Insider Activity
In other news, insider Janice Suzann Drew sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $22.63, for a total transaction of $452,600.00. Following the completion of the sale, the insider owned 67,794 shares of the company’s stock, valued at approximately $1,534,178.22. This represents a 22.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Luis C. Pena sold 7,438 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $22.71, for a total transaction of $168,916.98. Following the sale, the chief executive officer owned 630,458 shares in the company, valued at $14,317,701.18. This represents a 1.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 100,854 shares of company stock valued at $2,279,142.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Capricorn Fund Managers Ltd acquired a new stake in shares of Evommune in the 4th quarter valued at $1,027,000. Sofinnova Investments Inc. acquired a new position in shares of Evommune during the 4th quarter worth $2,625,000. Seven Grand Managers LLC acquired a new position in shares of Evommune during the 4th quarter worth $1,284,000. NEXTBio Capital Management LP bought a new stake in shares of Evommune during the 4th quarter worth $3,908,000. Finally, Monashee Investment Management LLC bought a new stake in shares of Evommune during the 4th quarter worth $3,137,000.
Evommune Company Profile
Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.
Featured Stories
- Five stocks we like better than Evommune
- The SK Hynix IPO and 2027’s AI Memory Squeeze
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
Receive News & Ratings for Evommune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evommune and related companies with MarketBeat.com's FREE daily email newsletter.
